CERTCertara, Inc.
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~3% a year FCF growth. Roughly in line with its three-year revenue growth of 5% a year.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CERT's price assumes
Today's price asks for 3.3% free cash flow growth a year; over the last three years Certara, Inc. delivered −2.4%, the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 6.0%
Free cash flow yield · Health Information Services median 6.3%
- Growth the price implies
- +3.3%
Growth the price implies · The price pays for +3.3% free cash flow growth a year for a decade; the business has delivered −2.4% a year over the last three.
- Price / book
- 0.87
Price / book · as of 2026-Q1
Details›
- Price / bookas of 2026-Q1
- 0.87
- EV / EBIToperating margin −0.16%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 2.47
- Free cash flow, trailing twelve months
- $80M
- Market capitalisation
- $1.34B
- 3-year revenue growth
- +5.1%
- 3-year free cash flow growth
- −2.4%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #9 of 20 by RyuScore